Bupivacaine Liposome Injection Research:CAGR of 8.60% during the forecast period

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Bupivacaine Liposome Injection- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.



The global market for Bupivacaine Liposome Injection was estimated to be worth US$ 553 million in 2024 and is forecast to a readjusted size of US$ 976 million by 2031 with a CAGR of 8.6% during the forecast period 2025-2031.



【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】

https://www.qyresearch.com/reports/3604231/bupivacaine-liposome-injection

Bupivacaine Liposome Injection Market Summary

Bupivacaine liposome injection is a long-acting amide local anesthetic. Traditional bupivacaine injections typically provide less than 8 hours of pain relief. In contrast, bupivacaine liposome injection is a long-acting sustained-release formulation that uses the advanced DepoFoam technology to encapsulate bupivacaine in multivesicular liposomes. After injection, the bupivacaine is gradually released as the liposome vesicles break open. Each vesicle releases a limited amount of drug, but the cumulative effect of multiple vesicles breaking at different times extends the release duration. This mechanism enables bupivacaine to provide pain relief for up to 72 hours, far surpassing the 6 to 8 hours typically offered by traditional local anesthetics.

This liposome injection offers sustained pain relief with a single dose, eliminating the need for additional equipment such as catheters and pain pumps. This not only simplifies medical procedures but also enhances patient comfort and compliance, while reducing equipment costs. Bupivacaine liposome injection provides a more convenient and effective solution for postoperative pain management.

According to the new market research report "Global Bupivacaine Liposome Injection Market Report 2024-2030", published by QYResearch, the global Bupivacaine Liposome Injection market size is projected to grow from USD 538.75 million in 2023 to USD 907.30 million by 2030, at a CAGR of 8.60% during the forecast period.

Global Bupivacaine Liposome Injection MarketSize(US$ Million), 2019-2030
250212-172631.webp (14 KB)

Above data is based on report from QYResearch: Global Bupivacaine Liposome Injection Market Report 2024-2030 (published in 2024). If you need the latest data, plaese contact QYResearch.



Global Bupivacaine Liposome Injection Top2Players Ranking and Market Share (Ranking is based on the revenue of 2023, continually updated)
250212-172658.webp (9 KB)

Above data is based on report from QYResearch: Global Bupivacaine Liposome Injection Market Report 2024-2030 (published in 2024). If you need the latest data, plaese contact QYResearch.

Global key manufacturers of bupivacaine liposome injection include Pacira Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals. In 2022, Jiangsu Hengrui Pharmaceuticals successfully obtained approval for the marketing of bupivacaine liposome injection in China, becoming the world's first generic version of this product. In China, besides Jiangsu Hengrui Pharmaceuticals, Kelun Pharmaceutical and Zhejiang Sundoc Pharmaceutical have also entered this market. In October 2024, Kelun Pharmaceutical's subsidiary, Hunan Kelun Pharmaceutical, received approval for its bupivacaine liposome injection, which was considered equivalent to passing consistency evaluation, making it the second approved product in China.

With the accelerated aging of China's population and a steadily increasing number of surgical patients, there is a growing demand for long-term, sustained, and safe postoperative pain relief drugs. Bupivacaine liposome injection has broad market prospects in China.





The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.



The Bupivacaine Liposome Injection market is segmented as below:

By Company

Pacira Pharmaceuticals
Jiangsu Hengrui Pharma



Segment by Type

133mg per Vial
266mg per Vial



Segment by Application

Hospital
Clinic



Each chapter of the report provides detailed information for readers to further understand the Bupivacaine Liposome Injection market:

Chapter 1: Introduces the report scope of the Bupivacaine Liposome Injection report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2020-2031)

Chapter 2: Detailed analysis of Bupivacaine Liposome Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2020-2025)

Chapter 3: Provides the analysis of various Bupivacaine Liposome Injection market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2020-2031)

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2020-2031)

Chapter 5: Sales, revenue of Bupivacaine Liposome Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2020-2031)

Chapter 6: Sales, revenue of Bupivacaine Liposome Injection in country level. It provides sigmate data by Type, and by Application for each country/region.(2020-2031)

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2020-2025)

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.



Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Bupivacaine Liposome Injection competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Bupivacaine Liposome Injection comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Bupivacaine Liposome Injection market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.



Other relevant reports of QYResearch:

Global Bupivacaine Liposome Injection Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Bupivacaine Liposome Injection Market Research Report 2025
Global and United States Bupivacaine Liposome Injection Market Report & Forecast 2024-2030
Global Bupivacaine Liposome Injection Market Research Report 2024
Global Bupivacaine Liposome Injection Market Insights, Forecast to 2030
Bupivacaine Liposome Injection- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

About Us：

QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)  
JP: https://www.qyresearch.co.jp

This release was published on openPR.